论文部分内容阅读
We are currently in the midst of a revolution in ageing research,with several dietary,genetic and pharmacological interventions now known to modulate ageing in model organisms.Excitingly,these interventions also appear to have beneficial effects on late-life health.For example,dietary restriction(DR) has been shown to slow the incidence of age-associated cardiovascular disease,metabolic disease,cancer and brain ageing in non-human primates and has been shown to improve a range of health indices in humans.While the idea that DR’s ability to extend lifespan is often thought of as being universal,studies in a range of organisms,including yeast,mice and monkeys,suggest that this may not actually be the case.The precise reasons underlying these differential effects of DR on lifespan are currently unclear,but genetic background may be an important factor in how an individual responds to DR.Similarly,recent findings also suggest that the responsiveness of mice to specific genetic or pharmacological interventions that modulate ageing may again be influenced by genetic background.Consequently,while there is a clear driver to develop interventions to improve late-life health and vitality,understanding precisely how these act in response to particular genotypes is critical if we are to translate these findings to humans.We will consider of the role of genetic background in the efficacy of various lifespan interventions and discuss potential routes of utilising genetic heterogeneity to further understand how particular interventions modulate lifespan and healthspan.
We are currently in the midst of a revolution in aging research, with several dietary, genetic and pharmacological interventions now known to modulate aging in model organisms. Exercising, these interventions also appear to have beneficial effects on late-life health. For example, dietary restriction (DR) has been shown to slow the incidence of age-associated cardiovascular disease, metabolic disease, cancer and brain aging in non-human primates and has been shown to improve a range of health indices in humans. Whilst the idea that DR’s ability to extend lifespan is often thought of as being universal, studies in a range of organisms, including yeast, mice and monkeys, suggest that this may not actually be the case. The precise principle underlying these differential effects of DR on lifespan are currently unclear, but genetic background may be an important factor in how an individual responds to DR.Similarly, recent findings also suggest that the responsiveness of mice to specific genetic or pharmacol ogical interventions that modulate aging may again be influenced by genetic background. Conclusion, while there is a clear driver to develop interventions to improve late-life health and vitality, understanding precisely how these act in response to particular genotypes is critical if we are to translate these findings to humans.We will consider of the role of genetic background in the efficacy of various lifespan interventions and discuss potential routes of utilising genetic heterogeneity to further understand how particular interventions modulate lifespan and healthspan.